173 related articles for article (PubMed ID: 24586533)
1. Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.
Chiang KC; Tsui KH; Chung LC; Yeh CN; Chang PL; Chen WT; Juang HH
PLoS One; 2014; 9(2):e89117. PubMed ID: 24586533
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.
Chiang KC; Tsui KH; Chung LC; Yeh CN; Feng TH; Chen WT; Chang PL; Chiang HY; Juang HH
Sci Rep; 2014 Jul; 4():5511. PubMed ID: 24981574
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
[TBL] [Abstract][Full Text] [Related]
4. BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells.
Tsui KH; Chiang KC; Lin YH; Chang KS; Feng TH; Juang HH
Cancer Med; 2018 Jan; 7(1):184-195. PubMed ID: 29239139
[TBL] [Abstract][Full Text] [Related]
5. L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.
Chung LC; Tsui KH; Feng TH; Lee SL; Chang PL; Juang HH
Am J Physiol Cell Physiol; 2012 Feb; 302(4):C676-85. PubMed ID: 22116304
[TBL] [Abstract][Full Text] [Related]
6. BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity.
Hu XD; Meng QH; Xu JY; Jiao Y; Ge CM; Jacob A; Wang P; Rosen EM; Fan S
Biochem Biophys Res Commun; 2011 Jan; 404(4):903-9. PubMed ID: 21172304
[TBL] [Abstract][Full Text] [Related]
7. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2.
Tsui KH; Hsieh WC; Lin MH; Chang PL; Juang HH
Prostate; 2008 May; 68(6):610-9. PubMed ID: 18196550
[TBL] [Abstract][Full Text] [Related]
8. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
9. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
Hsu JC; Zhang J; Dev A; Wing A; Bjeldanes LF; Firestone GL
Carcinogenesis; 2005 Nov; 26(11):1896-904. PubMed ID: 15958518
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer.
Rokhlin OW; Scheinker VS; Taghiyev AF; Bumcrot D; Glover RA; Cohen MB
Cancer Biol Ther; 2008 Aug; 7(8):1288-96. PubMed ID: 18497571
[TBL] [Abstract][Full Text] [Related]
11. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
Jalava SE; Urbanucci A; Latonen L; Waltering KK; Sahu B; Jänne OA; Seppälä J; Lähdesmäki H; Tammela TL; Visakorpi T
Oncogene; 2012 Oct; 31(41):4460-71. PubMed ID: 22266859
[TBL] [Abstract][Full Text] [Related]
12. Anti-androgen receptor signaling and prostate cancer inhibitory effects of sucrose- and benzophenone-compounds.
Wang Z; Lee HJ; Wang L; Jiang C; Baek NI; Kim SH; Lü J
Pharm Res; 2009 May; 26(5):1140-8. PubMed ID: 19266268
[TBL] [Abstract][Full Text] [Related]
13. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis.
Ficazzola MA; Fraiman M; Gitlin J; Woo K; Melamed J; Rubin MA; Walden PD
Carcinogenesis; 2001 Aug; 22(8):1271-9. PubMed ID: 11470758
[TBL] [Abstract][Full Text] [Related]
15. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
[TBL] [Abstract][Full Text] [Related]
16. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
17. Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.
Chung LC; Tsui KH; Feng TH; Lee SL; Chang PL; Juang HH
Mol Nutr Food Res; 2011 Nov; 55(11):1666-76. PubMed ID: 21936051
[TBL] [Abstract][Full Text] [Related]
18. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
19. B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage.
Lim YB; Park TJ; Lim IK
J Biol Chem; 2008 Nov; 283(48):33110-8. PubMed ID: 18840609
[TBL] [Abstract][Full Text] [Related]
20. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
